The present invention discloses compounds according to Formula I: ##STR00001##
Wherein R.sup.1, L.sub.1, R.sup.2, L.sub.2, R.sup.3, Cy, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL12 and/or IL23 by administering the compound of the invention.

The present invention provides a method for the synthesis of an injectable composition comprising a [.sup.18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises a method of radiosynthesis that permits a more facile purification using solid phase extraction (SPE).

Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

##STR00001##

Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein α, β, n, R.sup.4, R.sup.5, R.sup.6, R.sup.8, R.sup.9, R.sup.10, R.sup.11, X.sup.1, X.sup.2, X.sup.3 and X.sup.7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions comprising them, and to their use for treating diseases, disorders, and conditions associated with GPR139.

##STR00001##

The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

##STR00001##

Provided are: a compound that further improves the capability of an organic EL device, an organic electroluminescent device having a further improved device capability, and an electronic device including the organic electroluminescent device. Precisely provided are: a compound represented by the following formula (1A) or formula (1B) (wherein the symbols are as defined in the description), an organic electroluminescent device containing the compound, and an electronic device including the organic electroluminescent device.

##STR00001##

Disclosed are a deuterated compound of fomula (I), or a salt thereof, and methods for preparation thereof. The present disclosure may provide a mild, versatile organophotoredox method for the preparation of diverse, enantioenriched α-deuterated α-amino acids. In particular, the present disclosure may address the long-standing challenge of installing sterically demanding side chains into α-amino acids, including late-stage modifications on medicinal agents and natural products.

Provided are a triarylamine derivative and an organic electroluminescent device thereof, which relate to the technical field of organic electroluminescence. The triarylamine derivative has a relatively high triplet energy level, high hole mobility, a high refractive index and good film formability and thermal stability and can effectively reduce the driving voltage of the organic electroluminescent device, improve the luminescence efficiency, and extend the service life of the device when applied to the organic electroluminescent device. The triarylamine derivative has a good application effect and a good industrialization prospect in the organic electroluminescent device.

A compound comprising a first ligand L.sub.A of Formula I

##STR00001##

is described. In Formula I, X.sup.1 and X.sup.6 to X.sup.10 are each independently C or N; X.sup.2 is CR.sup.1′ or N; X.sup.3 is CR.sup.1 or N; X.sup.4 is CR.sup.2 or N; X.sup.5 is CR.sup.3 or N; each R.sup.1, R.sup.2, R.sup.3, R.sup.A, R.sup.B, and R.sup.C is independently a hydrogen or a General Substituent; any two substituents may be joined or fused to form a ring; at least one of R.sup.1′, R.sup.1, R.sup.2, and R.sup.3 is a partially or fully deuterated alkyl or cycloalkyl group; at least one pair of R.sup.C are joined or fused to form a 5-membered or 6-membered ring. Formulations, OLEDs, and consumer products comprising the compound are also described.

A composition including a first compound and a second compound, wherein the first compound is an organometallic compound including platinum and a tetradentate ligand bound thereto, and the second compound is an organometallic compound including iridium, μ(Pt) is about 0.5 debye to about 5.0 debye, μ(Pt) is less than μ(Ir), μ(Pt) is a dipole moment of the first compound, μ(Ir) is a dipole moment of the second compound, and each of μ(Pt) and μ(Ir) is calculated based on density functional theory as described herein.